Propelling the Future
is to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC® protein degradation platform.
We are Arvinas, a clinical-stage biotechnology company leading the way in the development of targeted protein degradation therapeutics.
We are singularly focused on developing an entirely new class of medicines that aims to be transformative for patients and their health care providers, turning targeted protein degradation into one of the most promising areas of medical research and challenging the perceived limits of drug discovery.
If you’re inspired, please take a look at the current list of opportunities to join our team.
Our Hope is to Revolutionize Drug Discovery
Our team is driving some of the most significant breakthroughs in the industry and enabling an expansive pipeline of targets in oncology and neuroscience.
Together, we are bringing novel investigational research to patients who need it most. With multiple products in development, we are exploring how PROTAC® protein degraders bridge our preclinical platform into the clinic.
Learn more about our therapeutic programs.
Leading the Way with Innovation
Proud of Our People
We embrace the freedom to pursue innovation, think creatively and continually strive to create a diverse, equitable and inclusive colleague community—and we actively recruit talent who share these values. Explore our open positions to learn more.
Promoting Our Values
Arvinas is rooted in scientific innovation and is committed to bringing new options to patients living with life-threatening and life-altering diseases, especially cancer and neurologic disorders.
Our Promise to Patients
We are unwavering in our mission to bring new treatments to patients through targeted protein degraders. We strive to be a trusted ally to the patient advocacy community and work to better understand the needs of patients, their families, and caregivers as we advance our drug development process.
We are Part of a Community
Our proprietary PROTAC® protein degrader technology was built upon groundbreaking research of our founder Dr. Craig Crews of Yale University, and we are especially proud of our New Haven roots. Beyond drug development, we are committed to our emerging biotechnology community in New Haven.
Join the Conversation
Partnerships are a Pivotal Part of Our Process
We partner with leading drug companies, academic experts, and innovative partners to further broaden and accelerate our clinical programs.
We’re excited about the work we’re doing inside and outside of Arvinas, and think you will be, too.